Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Yu
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Keros Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research is focused on investigating the BMP/TGF-b pathway and its role in heterotopic ossification by identifying and validating candidate small molecules that modulate ALK2, ALK3, and ALK6. Keros Therapeutics is a biotechnology company focused on developing treatments for fibrodysplasia ossificans progressive and other heterotopic ossification disorders. Keros’ main candidate is an ALK2 inhibitor. The results of the research could have an effect on Keros’ financial interests if the study validates ALK2 inhibitors or provides further insight into the role they play in the BMP/TGF-b pathway. Because Dr. Yu holds an equity interest in Keros, the significant financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Molecular and cellular mechanisms of heterotopic ossification
This proposal asks how bone morphogenetic protein signals, which normally regulate the activity of progenitor cells involved in the repair of muscle, blood vessels, connective tissues, and bone, may become dysregulated to cause disabling bone formation in muscle, tendons and ligaments in heterotopic ossification disease. In addition to providing insights and tools for understanding how bone morphogenetic proteins regulate this process, these studies may lead to more tolerable and effective therapies. The underlying mechanism of heterotopic ossification has relevance to a broader set of conditions in which inflammation and injury lead to abnormal ossification of diverse tissues in autoimmune, degenerative, and cardiovascular disease.
Filed on August 07, 2018.
Tell us what you know about Paul Yu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Paul Yu filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $20,000 - $39,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $20,000 - $39,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $10,000 - $19,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | Value cannot be readily determined |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.